1
|
Wang X, Zhang K, Yang F, Ren Z, Xu M,
Frank JA, Ke ZJ and Luo J: Minocycline protects developing brain
against ethanol-induced damage. Neuropharmacology. 129:84–99. 2018.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Debell F, Fear NT, Head M, Batt-Rawden S,
Greenberg N, Wessely S and Goodwin L: A systematic review of the
comorbidity between PTSD and alcohol misuse. Soc Psychiatry
Psychiatr Epidemiol. 49:1401–1425. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Pietrzak RH, Goldstein RB, Southwick SM
and Grant BF: Prevalence and Axis I comorbidity of full and partial
posttraumatic stress disorder in the United States: Results from
Wave 2 of the national epidemiologic survey on alcohol and related
conditions. J Anxiety Disord. 25:456–465. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Neupane SP, Bramness JG and Lien L:
Comorbid post-traumatic stress disorder in alcohol use disorder:
Relationships to demography, drinking and neuroimmune profile. BMC
Psychiatry. 17:3122017. View Article : Google Scholar : PubMed/NCBI
|
5
|
Franck J and Jayaram-Lindström N:
Pharmacotherapy for alcohol dependence: Status of current
treatments. Curr Opin Neurobiol. 23:692–699. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Soyka M and Müller CA: Pharmacotherapy of
alcoholism-an update on approved and off-label medications. Expert
Opin Pharmacother. 18:1187–1199. 2017. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hillemacher T and Frieling H:
Pharmacotherapeutic options for co-morbid depression and alcohol
dependence. Expert Opin Pharmacother. 20:547–569. 2019. View Article : Google Scholar : PubMed/NCBI
|
8
|
Garbutt JC: The state of pharmacotherapy
for the treatment of alcohol dependence. J Subst Abuse Treat.
36:S15–S25. 2009.PubMed/NCBI
|
9
|
Szabo G, Mandrekar P, Petrasek J and
Catalano D: The unfolding web of innate immune dysregulation in
alcoholic liver injury. Alcohol Clin Exp Res. 35:782–786. 2011.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Qin L, He J, Hanes RN, Pluzarev O, Hong JS
and Crews FT: Increased systemic and brain cytokine production and
neuroinflammation by endotoxin following ethanol treatment. J
Neuroinflammation. 5:102008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kalejaiye O, Getachew B, Ferguson CL,
Taylor RE and Tizabi Y: Alcohol-induced increases in inflammatory
cytokines are attenuated by nicotine in region-selective manner in
male rats. J Drug Alcohol Res. 6(pii): 2360362017.PubMed/NCBI
|
12
|
McClain C, Barve S, Deaciuc I, Kugelmas M
and Hill D: Cytokines in alcoholic liver disease. Semin Liver Dis.
19:205–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
13
|
McClain CJ and Cohen DA: Increased tumor
necrosis factor production by monocytes in alcoholic hepatitis.
Hepatology. 9:349–351. 1989. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ahluwalia B, Wesley B, Adeyiga O, Smith
DM, Da-Silva A and Rajguru S: Alcohol modulates cytokine secretion
and synthesis in human fetus: an in vivo and in vitro study.
Alcohol. 21:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Nicoletti F, Zaccone P, Di Marco R,
Lunetta M, Magro G, Grasso S, Meroni P and Garotta G: Prevention of
spontaneous autoimmune diabetes in diabetes-prone BB rats by
prophylactic treatment with antirat interferon-gamma antibody.
Endocrinology. 138:281–288. 1997. View Article : Google Scholar : PubMed/NCBI
|
16
|
Nicoletti F, Mancuso G, Cusumano V, Di
Marco R, Zaccone P, Bendtzen K and Teti G: Prevention of
endotoxin-induced lethality in neonatal mice by interleukin-13. Eur
J Immunol. 27:1580–1583. 1997. View Article : Google Scholar : PubMed/NCBI
|
17
|
Marchant A, Bruyns C, Vandenabeele P,
Ducarme M, Gérard C, Delvaux A, De Groote D, Abramowicz D, Velu T
and Goldman M: Interleukin-10 controls interferon-gamma and tumor
necrosis factor production during experimental endotoxemia. Eur J
Immunol. 24:1167–1171. 1994. View Article : Google Scholar : PubMed/NCBI
|
18
|
González-Reimers E, Santolaria-Fernández
F, Medina-García JA, González-Pérez JM, de la Vega-Prieto MJ,
Medina-Vega L, Martín-González C and Durán-Castellón MC: TH-1 and
TH-2 cytokines in stable chronic alcoholics. Alcohol Alcohol.
47:390–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Nicoletti F, Di Marco R, Patti F, Reggio
E, Nicoletti A, Zaccone P, Stivala F, Meroni PL and Reggio A: Blood
levels of transforming growth factor-beta 1 (TGF-beta1) are
elevated in both relapsing remitting and chronic progressive
multiple sclerosis (MS) patients and are further augmented by
treatment with interferon-beta 1b (IFN-beta1b). Clin Exp Immunol.
113:96–99. 1998. View Article : Google Scholar : PubMed/NCBI
|
20
|
Crews FT, Bechara R, Brown LA, Guidot DM,
Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M and Zou J: Cytokines
and alcohol. Alcohol Clin Exp Res. 30:720–730. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Nikou T, Ioannidis A, Zoga M, Tzavellas E,
Paparrigopoulos T, Magana M, Pliatsika P, Nikolaou C and
Chatzipanagiotou S: Alteration in the concentrations of
Interleukin-7 (IL-7), Interleukin-10 (IL-10) and Granulocyte Colony
Stimulating Factor (G-CSF) in alcohol-dependent individuals without
liver disease, during detoxification therapy. Drug Alcohol Depend.
163:77–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Archer M, Kampman O, Bloigu A, Bloigu R,
Luoto K, Kultti J, Hämäläinen M, Moilanen E, Leinonen E and Niemelä
O: Assessment of alcohol consumption in depression follow-up using
self-reports and blood measures including inflammatory biomarkers.
Alcohol Alcohol. 54:243–250. 2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Heberlein A, Käser M, Lichtinghagen R,
Rhein M, Lenz B, Kornhuber J, Bleich S and Hillemacher T: TNF-α and
IL-6 serum levels: Neurobiological markers of alcohol consumption
in alcohol-dependent patients? Alcohol. 48:671–676. 2014.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Lippai D, Bala S, Petrasek J, Csak T,
Levin I, Kurt-Jones EA and Szabo G: Alcohol-induced IL-1β in the
brain is mediated by NLRP3/ASC inflammasome activation that
amplifies neuroinflammation. J Leukoc Biol. 94:171–182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Warden AS, Azzam M, DaCosta A, Mason S,
Blednov YA, Messing RO, Mayfield RD and Harris RA: Toll-like
receptor 3 activation increases voluntary alcohol intake in
C57BL/6J male mice. Brain Behav Immun. 77:55–65. 2019. View Article : Google Scholar : PubMed/NCBI
|
26
|
McCarthy GM, Warden AS, Bridges CR,
Blednov YA and Harris RA: Chronic ethanol consumption: Role of
TLR3/TRIF-dependent signaling. Addict Biol. 23:889–903. 2018.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Nennig SE and Schank JR: The role of NFkB
in drug addiction: Beyond inflammation. Alcohol Alcohol.
52:172–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Coleman LG Jr, Zou J, Qin L and Crews FT:
HMGB1/IL-1β complexes regulate neuroimmune responses in alcoholism.
Brain Behav Immun. 72:61–77. 2018. View Article : Google Scholar : PubMed/NCBI
|
29
|
Crews FT and Vetreno RP: Mechanisms of
neuroimmune gene induction in alcoholism. Psychopharmacology
(Berl). 233:1543–1557. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
González-Reimers E, Santolaria-Fernández
F, Martín-González MC, Fernández-Rodríguez CM and Quintero-Platt G:
Alcoholism: A systemic proinflammatory condition. World J
Gastroenterol. 20:14660–14671. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Bell RL, Lopez MF, Cui C, Egli M, Johnson
KW, Franklin KM and Becker HC: Ibudilast reduces alcohol drinking
in multiple animal models of alcohol dependence. Addict Biol.
20:38–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Ray LA, Bujarski S, Shoptaw S, Roche DJ,
Heinzerling K and Miotto K: Development of the neuroimmune
modulator ibudilast for the treatment of alcoholism: A randomized,
placebo-controlled, human laboratory trial.
Neuropsychopharmacology. 42:1776–1788. 2017. View Article : Google Scholar : PubMed/NCBI
|
33
|
da Silva e Silva DA, Frozino Ribeiro A,
Damasceno S, Rocha CS, Berenguer de Matos AH, Boerngen-Lacerda R,
Correia D and Brunialti Godard AL: Inflexible ethanol intake: A
putative link with the Lrrk2 pathway. Behav Brain Res. 313:30–37.
2016. View Article : Google Scholar : PubMed/NCBI
|
34
|
Sutherland GT, Sheedy D, Sheahan PJ,
Kaplan W and Kril JJ: Comorbidities, confounders, and the white
matter transcriptome in chronic alcoholism. Alcohol Clin Exp Res.
38:994–1001. 2014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Sheedy D, Garrick T, Dedova I, Hunt C,
Miller R, Sundqvist N and Harper C: An Australian brain bank: A
critical investment with a high return! Cell Tissue Bank.
9:205–216. 2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Xu H, Wang F, Liu Y, Yu Y, Gelernter J and
Zhang H: Sex-biased methylome and transcriptome in human prefrontal
cortex. Hum Mol Genet. 23:1260–1270. 2014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Beech RD, Leffert JJ, Lin A, Hong KA,
Hansen J, Umlauf S, Mane S, Zhao H and Sinha R: Stress-related
alcohol consumption in heavy drinkers correlates with expression of
miR-10a, miR-21, and components of the TAR-RNA-binding
protein-associated complex. Alcohol Clin Exp Res. 38:2743–2753.
2014. View Article : Google Scholar : PubMed/NCBI
|
38
|
Günther S, Fagone P, Jalce G, Atanasov AG,
Guignabert C and Nicoletti F: Role of MIF and D-DT in
immune-inflammatory, autoimmune, and chronic respiratory diseases:
From pathogenic factors to therapeutic targets. Drug Discov Today.
24:428–439. 2019. View Article : Google Scholar : PubMed/NCBI
|
39
|
Crews FT, Lawrimore CJ, Walter TJ and
Coleman LG: The role of neuroimmune signaling in alcoholism.
Neuropharmacology. 122:56–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
40
|
Alfonso-Loeches S, Pascual-Lucas M, Blanco
AM, Sanchez-Vera I and Guerri C: Pivotal role of TLR4 receptors in
alcohol-induced neuroinflammation and brain damage. J Neurosci.
30:8285–8295. 2010. View Article : Google Scholar : PubMed/NCBI
|
41
|
Petrakis IL, Ralevski E, Gueorguieva R,
Sloan ME, Devine L, Yoon G, Arias AJ and Sofuoglu M: Targeting
neuroinflammation with minocycline in heavy drinkers.
Psychopharmacology (Berl). 236:3013–3021. 2019. View Article : Google Scholar : PubMed/NCBI
|
42
|
Nicoletti F, Mazzon E, Fagone P, Mangano
K, Mammana S, Cavalli E, Basile MS, Bramanti P, Scalabrino G, Lange
A and Curtin F: Prevention of clinical and histological signs of
MOG-induced experimental allergic encephalomyelitis by prolonged
treatment with recombinant human EGF. J Neuroimmunol. 332:224–232.
2019. View Article : Google Scholar : PubMed/NCBI
|
43
|
Fagone P, Mazzon E, Cavalli E, Bramanti A,
Petralia MC, Mangano K, Al-Abed Y, Bramati P and Nicoletti F:
Contribution of the macrophage migration inhibitory factor
superfamily of cytokines in the pathogenesis of preclinical and
human multiple sclerosis: In silico and in vivo evidences. J
Neuroimmunol. 322:46–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
44
|
Cavalli E, Mazzon E, Basile MS, Mangano K,
Di Marco R, Bramanti P, Nicoletti F, Fagone P and Petralia MC:
Upregulated expression of macrophage migration inhibitory factor,
its analogue D-dopachrome tautomerase, and the CD44 receptor in
peripheral CD4 T cells from clinically isolated syndrome patients
with rapid conversion to clinical defined multiple sclerosis.
Medicina (Kaunas). 55(pii): E6672019. View Article : Google Scholar : PubMed/NCBI
|
45
|
Lombardo SD, Presti M, Mangano K, Petralia
MC, Basile MS, Libra M, Candido S, Fagone P, Mazzon E, Nicoletti F
and Bramanti A: Prediction of PD-L1 expression in neuroblastoma via
computational modeling. Brain Sci. 9(pii): E2212019. View Article : Google Scholar : PubMed/NCBI
|
46
|
Presti M, Mazzon E, Basile M, Petralia MC,
Bramanti A, Colletti G, Bramanti P, Nicoletti F and Fagone P:
Overexpression of macrophage migration inhibitory factor and
functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in
glioblastoma. Oncol Lett. 16:2881–2886. 2018.PubMed/NCBI
|
47
|
Mangano K, Mazzon E, Basile MS, Di Marco
R, Bramanti P, Mammana S, Petralia MC, Fagone P and Nicoletti F:
Pathogenic role for macrophage migration inhibitory factor in
glioblastoma and its targeting with specific inhibitors as novel
tailored therapeutic approach. Oncotarget. 9:17951–17970. 2018.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Fagone P, Mangano K, Mammana S, Pesce A,
Pesce A, Caltabiano R, Giorlandino A, Portale TR, Cavalli E,
Lombardo GA, et al: Identification of novel targets for the
diagnosis and treatment of liver fibrosis. Int J Mol Med.
36:747–752. 2015. View Article : Google Scholar : PubMed/NCBI
|
49
|
Lombardo SD, Mazzon E, Basile MS, Campo G,
Corsico F, Presti M, Bramanti P, Mangano K, Petralia MC, Nicoletti
F and Fagone P: Modulation of tetraspanin 32 (TSPAN32) expression
in T cell-mediated immune responses and in multiple sclerosis. Int
J Mol Sci. 20(pii): E43232019. View Article : Google Scholar : PubMed/NCBI
|
50
|
Candido S, Lupo G, Pennisi M, Basile MS,
Anfuso CD, Petralia MC, Gattuso G, Vivarelli S, Spandidos DA, Libra
M and Falzone L: The analysis of miRNA expression profiling
datasets reveals inverse microRNA patterns in glioblastoma and
Alzheimer's disease. Oncol Rep. 42:911–922. 2019.PubMed/NCBI
|
51
|
Petralia MC, Mazzon E, Fagone P, Falzone
L, Bramanti P, Nicoletti F and Basile MS: Retrospective follow-up
analysis of the transcriptomic patterns of cytokines, cytokine
receptors and chemokines at preconception and during pregnancy, in
women with post-partum depression. Exp Ther Med. 18:2055–2062.
2019.PubMed/NCBI
|
52
|
Mangano K, Lanteri R, Basile MS, Bellavia
N, Latino R, Messina D, Fagone P, Colletti G, Nania R, Caltabiano
R, et al: Effects of GIT-27NO, a NO-donating compound, on hepatic
ischemia/reperfusion injury. Int J Immunopathol Pharmacol.
33:20587384198627362019. View Article : Google Scholar : PubMed/NCBI
|
53
|
Lombardo SD, Mazzon E, Basile MS, Cavalli
E, Bramanti P, Nania R, Fagone P, Nicoletti F and Petralia MC:
Upregulation of IL-1 receptor antagonist in a mouse model of
migraine. Brain Sci. 9(pii): E1722019. View Article : Google Scholar : PubMed/NCBI
|
54
|
Mammana S, Bramanti P, Mazzon E, Cavalli
E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F and
Mangano K: Preclinical evaluation of the PI3K/Akt/mTOR pathway in
animal models of multiple sclerosis. Oncotarget. 9:8263–8277. 2018.
View Article : Google Scholar : PubMed/NCBI
|
55
|
Mangano K, Cavalli E, Mammana S, Basile
MS, Caltabiano R, Pesce A, Puleo S, Atanasov AG, Magro G, Nicoletti
F and Fagone P: Involvement of the Nrf2/HO-1/CO axis and
therapeutic intervention with the CO-releasing molecule CORM-A1, in
a murine model of autoimmune hepatitis. J Cell Physiol.
233:4156–4165. 2018. View Article : Google Scholar : PubMed/NCBI
|
56
|
Petralia MC, Mazzon E, Fagone P, Russo A,
Longo A, Avitabile T, Nicoletti F, Reibaldi M and Basile MS:
Characterization of the pathophysiological role of CD47 in uveal
melanoma. Molecules. 24(pii): E24502019. View Article : Google Scholar : PubMed/NCBI
|
57
|
Basile MS, Fagone P, Mangano K, Mammana S,
Magro G, Salvatorelli L, Li Destri G, La Greca G, Nicoletti F,
Puleo S and Pesce A: KCNMA1 expression is downregulated in
colorectal cancer via epigenetic mechanisms. Cancers (Basel).
11(pii): E2452019. View Article : Google Scholar : PubMed/NCBI
|
58
|
Basile MS, Mazzon E, Russo A, Mammana S,
Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti
F, et al: Differential modulation and prognostic values of
immune-escape genes in uveal melanoma. PLoS One. 14:e02102762019.
View Article : Google Scholar : PubMed/NCBI
|
59
|
Fagone P, Caltabiano R, Russo A, Lupo G,
Anfuso CD, Basile MS, Longo A, Nicoletti F, De Pasquale R, Libra M
and Reibaldi M: Identification of novel chemotherapeutic strategies
for metastatic uveal melanoma. Sci Rep. 7:445642017. View Article : Google Scholar : PubMed/NCBI
|
60
|
Rajasekaran D, Zierow S, Syed M, Bucala R,
Bhandari V and Lolis EJ: Targeting distinct tautomerase sites of
D-DT and MIF with a single molecule for inhibition of neutrophil
lung recruitment. FASEB J. 28:4961–4971. 2014. View Article : Google Scholar : PubMed/NCBI
|
61
|
Benedek G, Meza-Romero R, Jordan K, Zhang
Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, et al: MIF
and D-DT are potential disease severity modifiers in male MS
subjects. Proc Natl Acad Sci USA. 114:E8421–E8429. 2017. View Article : Google Scholar : PubMed/NCBI
|